INSM vs. LEGN, ARNA, FTSV, CCXI, PTCT, ALNY, TEVA, GMAB, RPRX, and BMRN
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), Forty Seven (FTSV), ChemoCentryx (CCXI), PTC Therapeutics (PTCT), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN).
Insmed (NASDAQ:INSM) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
Legend Biotech has higher revenue and earnings than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
70.9% of Legend Biotech shares are held by institutional investors. 4.6% of Insmed shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Insmed had 2 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Insmed and 13 mentions for Legend Biotech. Insmed's average media sentiment score of 0.64 beat Legend Biotech's score of 0.41 indicating that Insmed is being referred to more favorably in the media.
Insmed received 455 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.28% of users gave Insmed an outperform vote while only 65.26% of users gave Legend Biotech an outperform vote.
Insmed currently has a consensus price target of $59.25, suggesting a potential upside of 4.22%. Legend Biotech has a consensus price target of $81.10, suggesting a potential upside of 77.97%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Insmed.
Legend Biotech has a net margin of -135.92% compared to Insmed's net margin of -236.74%. Insmed's return on equity of 0.00% beat Legend Biotech's return on equity.
Insmed has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.
Summary
Insmed beats Legend Biotech on 10 of the 17 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
